ABSTRACT

Purpose

To report a case of severe, recurrent bilateral panuveitis secondary to primary progressive multiple sclerosis responsive to ocrelizumab infusions.

Observation

We describe the clinical progression of a 40 year old female who presented with a 3-week history of insidious bilateral visual loss that was clinically consistent with panuveitis. A diagnosis of multiple sclerosis was established with serial magnetic resonance imaging (MRI) that coincided with focal neurological events separated by time. There was initially good response to high dose oral prednisolone; however, the patient would have recurrent uveitis each time the dose was weaned. Under guidance of neurology, we had initiated treatment with ocrelizumab with stability of ocular inflammation for the past 24 months.

Conclusion

Six-monthly 600mg ocrelizumab infusions may be effective as a steroid sparing option for patients with severe, recurrent bilateral panuveitis secondary to primary progressive multiple sclerosis.

中文翻译：

---

病例报告：继发于对 Ocrelizumab 有反应的原发性进行性多发性硬化症的复发性严重葡萄膜炎

摘要

目的

报告一例继发于对奥瑞珠单抗输注有反应的原发性进行性多发性硬化的严重、复发性双侧全葡萄膜炎病例。

观察

我们描述了一名 40 岁女性的临床进展，该女性有 3 周的隐匿性双侧视力丧失病史，临床上与全葡萄膜炎一致。多发性硬化症的诊断是通过连续磁共振成像 (MRI) 确定的，该成像与时间间隔的局灶性神经系统事件相吻合。最初对大剂量口服泼尼松龙反应良好；然而，患者每次停药后葡萄膜炎都会复发。在神经内科的指导下，我们在过去 24 个月内开始使用奥瑞珠单抗治疗，眼部炎症稳定。

结论

对于继发于原发性进行性多发性硬化症的严重、复发性双侧全葡萄膜炎患者，每六个月输注 600 毫克 ocrelizumab 可能是一种有效的类固醇保留选择。